BACKGROUND: To develop standardized metrics for expected outcomes in lower extremity revascularization for @entity63 ( @entity63 ), the Society for Vascular Surgery (SVS) has developed objective performance goals (OPGs) based on aggregate data from randomized trials of lower extremity bypass (LEB). It remains unknown, however, if these targets can be achieved in everyday vascular surgery practice. METHODS: We applied SVS @entity5299 criteria to 1039 @entity1 undergoing 1039 LEB operations for @entity63 with autogenous vein (excluding @entity1 on dialysis) within the @entity455 ( @entity455 ). Each of the individual OPGs was calculated within the @entity455 dataset, along with its surrounding 95% confidence intervals (CIs) and compared to published SVS OPGs using   (2) comparisons and survival analysis. RESULTS: Across most risk strata, @entity1 in the @entity455 and SVS @entity5299 cohorts were similar (clinical high-risk [age >80 years and tissue loss]: 15.3% @entity455 ; 16.2% SVS @entity5299 ; P = .58; anatomic high risk [infrapopliteal target artery]: 57.8% @entity455 ; 60.2% SVS @entity5299 ; P = .32). However, the proportion of @entity455 @entity1 designated as conduit high-risk (lack of single-segment great saphenous vein) was lower (10.2% @entity455 ; 26.9% SVS @entity5299 ;P < .001). The primary safety endpoint, major adverse limb events (MALE) at 30 days, was lower in the @entity455 cohort (3.2%; 95% CI, 2.3-4.6) than the SVS @entity5299 cohort (6.2%; 95% CI, 4.2-8.1; P = .05). The primary efficacy @entity5299 endpoint, freedom from any @entity204 within the first year (MALE + postoperative death [POD]), was similar between @entity455 and SVS @entity5299 cohorts (77%; 95% CI, 74%-80%) SVS @entity5299 , 74% (95% CI, 71%-77%) @entity455 , P = .58). In the remaining safety and efficacy OPGs, the @entity455 cohort met or exceeded the benchmarks established by the SVS @entity5299 cohort. CONCLUSION: Community and @entity4207 centers in everyday vascular surgery practice can meet OPGs derived from centers of excellence in LEB. Quality improvement initiatives, as well as clinical trials, should incorporate OPGs in their outcome measures to facilitate communication and comparison of risk-adjusted outcomes in the treatment of @entity63 .

Validation of the Society for Vascular Surgery's objective performance goals for XXXX in everyday vascular surgery practice.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity455 :: ('MESH:D014652', 'Disease') :: ['Vascular Study Group of New England', 'VSGNE'] @entity63 :: ('MESH:D007511', 'Disease') :: ['critical limb ischemia', 'CLI'] @entity5299 :: ('690', 'Gene') :: ['OPG'] @entity4207 :: ('MESH:D007859', 'Disease') :: ['academic'] @entity204 :: ('MESH:D003643', 'Disease') :: ['MALE or postoperative death']
@entity63 :: (MESH:D007511,Disease) :: ['critical limb ischemia']
